At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 87 enrolled
Drug / intervention
macrogol 3350-based oral osmotic laxative +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Polyethylene Glycol for ACF Reduction and Biomarker Modulation in Individuals With CRC Risk
In Brief
A Phase 2 clinical trial evaluating macrogol 3350-based oral osmotic laxative, Placebo, and 1 other intervention for Adenomatous Polyp and Colorectal Carcinoma. Completed, enrolled 87 participants across 3 sites.
Detailed Summary
This randomized phase II trial studies how well macrogol 3350-based oral osmotic laxative (polyethylene glycol 3350) works in preventing cancer in patients at risk of colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of macrogol 3350-based oral osmotic laxative may stop cancer from growing in patients who are at risk of colorectal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenomatous Polyp, Colorectal Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartOct 2009
Primary CompletionOct 2014
TodayJul 2026
First PostedJan 26, 2009
Enrollment StartOct 1, 2009
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 17.4 years ago
Interventions
macrogol 3350-based oral osmotic laxativedrug
Given PO
Placeboother
Given PO
Laboratory Biomarker Analysisother
Correlative studies